Related Experiment Video
Updated: Sep 13, 2025
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Comparing the Impact of Different Antiarrhythmic Classes on Clinical Outcomes Following Atrial Fibrillation Catheter
Andrej Belančić1, Yusuf Ziya Sener2, Metin Oksul3
1Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia.
Insights
Class IC and Class III antiarrhythmic drugs (AADs) show similar effectiveness in preventing atrial tachycardia recurrence after catheter ablation for atrial fibrillation (AF). Short-term use of these AADs is associated with negligible adverse events.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Catheter ablation is standard for drug-refractory atrial fibrillation (AF).
- Antiarrhythmic drugs (AADs) are used post-ablation to prevent recurrences.
- Limited data compares Class IC and Class III AADs efficacy and safety post-ablation.
Purpose of the Study:
- To compare the clinical outcomes of Class IC versus Class III AADs following AF catheter ablation.
- To evaluate the impact on arrhythmia recurrence and safety endpoints.
- To identify predictors of atrial tachycardia recurrence post-ablation.
Main Methods:
- Prospective study of 98 patients undergoing AF catheter ablation (Jan 2015-Nov 2024).
- Patients received either Class IC or Class III (amiodarone) AADs for two months post-ablation.
- Primary outcome: atrial tachycardia recurrence-free survival.
Main Results:
- No significant difference in atrial tachycardia recurrence rates between Class IC (9.7%) and Class III (19.4%) AAD groups (p=0.169).
- Predictors of recurrence included prior direct current cardioversion and left atrial diameter.
- Symptomatic bradycardia was the most common adverse event (6.1%), resolving with dose reduction.
Conclusions:
- Class IC and Class III AADs demonstrate comparable efficacy in preventing atrial tachycardia recurrence post-AF ablation.
- Short-term use of these AADs is safe with minimal adverse events.
- Further research may explore long-term outcomes and specific patient subgroups.
Abstract:
Background/Objectives: Catheter ablation has become the standard of care for patients with symptomatic and drug-refractory atrial fibrillation (AF). Both Class IC and Class III antiarrhythmic drugs (AADs) are effective in preventing early recurrences of AF, but not late recurrences, compared with the usual care. We aimed to compare the effects of two months of Class IC versus Class III AADs following AF catheter ablation on clinical outcomes, including arrhythmia recurrence and safety endpoints. Methods: All patients undergoing AF catheter ablation between January 2015 and November 2024 were screened, and cases meeting the inclusion criteria were included. Primary outcome was defined as atrial tachycardia recurrence-free survival. Results: A total of 98 patients (mean age 54.2 ± 14.0 years; 55.1% male) were enrolled, with 66.3% presenting with paroxysmal atrial fibrillation (AF). The mean left atrial diameter was 38.7 ± 5.1 mm, and 78.6% underwent cryoballoon ablation. Class IC AADs were administered to 62 cases, while the remaining 36 patients received amiodarone following catheter ablation. The rate of atrial tachycardia (ATa) recurrence was comparable between the patients treated with Class IC and Class III AADs (9.7% vs. 19.4%; p = 0.169). Predictors of ATa recurrence were identified as history of direct current cardioversion-DCCV (HR: 5.86; 95%CI: 1.44-23.82)-and LA diameter (HR: 1.17; 95%CI: 1.04-1.31). The most frequent AAD-related adverse event was symptomatic bradycardia (6.1%), which resolved in all cases following dose reduction. Conclusions: Class IC and Class III antiarrhythmics show comparable efficacy in terms of preventing ATa recurrence following AF catheter ablation. AAD-related adverse event rates are negligible for short-term use.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias